SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes

被引：0

作者：

Irene Fernández-Ruiz

机构：

[1] Nature Reviews Cardiology,

来源：

Nature Reviews Cardiology | 2024年 / 21卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular events by 20% compared with placebo in patients who are overweight or obese and with pre-existing cardiovascular disease but without diabetes mellitus, according to findings from the SELECT trial.

引用

页码：69 / 69

共 50 条

[21] Therapy insight: weight-loss surgery and major cardiovascular risk factors
Blackburn, GL
Mun, EC
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (11): : 585 - 591
[22] In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders
Rajagopal, Selvi
Cheskin, Lawrence J.
ANNALS OF INTERNAL MEDICINE, 2021, 174 (07) : JC80 - JC80
[23] Cardiovascular Outcome under Semaglutide SUSTAIN-6 study shows significant Risk Reduction
Fries, C.
DIABETOLOGE, 2016, 12 (08): : 582 - 583
[24] EFFECT OF MODEST WEIGHT-LOSS ON CHANGES IN CARDIOVASCULAR RISK-FACTORS - ARE THERE DIFFERENCES BETWEEN MEN AND WOMEN OR BETWEEN WEIGHT-LOSS AND MAINTENANCE
WING, RR
JEFFERY, RW
INTERNATIONAL JOURNAL OF OBESITY, 1995, 19 (01) : 67 - 73
[25] Multi-component weight-loss interventions for people with cardiovascular disease and/or type 2 diabetes mellitus: a systematic review
Gallagher, Robyn
Armari, Elizabeth
White, Haidee
Hollams, Daniel
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2013, 12 (04) : 320 - 329
[26] Cardiovascular Risk Reduction in Type 2 Diabetes: Further Insights into the Power of Weight Loss and Exercise
Lee, Seung-Hwan
ENDOCRINOLOGY AND METABOLISM, 2023, 38 (03) : 302 - 304
[27] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
Lingvay, Ildiko
Deanfield, John
Kahn, Steven E.
Weeke, Peter E.
Toplak, Hermann
Scirica, Benjamin M.
Ryden, Lars
Rathor, Naveen
Plutzky, Jorge
Morales, Cristobal
Lincoff, A. Michael
Lehrke, Michael
Jeppesen, Ole Kleist
Gajos, Grzegorz
Colhoun, Helen M.
Cariou, Bertrand
Ryan, Donna
DIABETES CARE, 2024, 47 (08)
[28] RELATIONSHIP OF WEIGHT-LOSS TO CARDIOVASCULAR RISK-FACTORS IN MORBIDLY OBESE INDIVIDUALS
ANDERSON, JW
BRINKMANKAPLAN, VL
LEE, H
WOOD, CL
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1994, 13 (03) : 256 - 261
[29] Metformin as a weight loss drug in obese children without diabetes?
Idris, Iskandar
DIABETES OBESITY & METABOLISM, 2014, 16 (03): : 287 - 287
[30] Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide
Tama, Elif
Fansa, Sima
Anazco, Diego
Rivera, Rene
Ghusn, Wissam
Cifuentes, Lizeth
Acosta, Andres
Hurtado, Maria D.
DIABETES, 2024, 73

← 1 2 3 4 5 →